GlassScriptPhysician profile
Leandro R Ramirez
NPI 1063073146
$4,385.98
in general payments reported to CMS, 2019-2025
28 companies · $1,027 in 2025
The $1,027 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $320 · 2020: $91.99 · 2021: $591 · 2022: $750 · 2023: $986 · 2024: $621 · 2025: $1,027.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,539 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,538.78 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $834.37 | 2020-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $552.33 | 2023-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Janssen Pharmaceuticals, INC | $355.30 | 2020-2023 | Xarelto |
| Gilead Sciences, INC. | $322.69 | 2020-2022 | |
| Mylan Specialty L.P. | $274.25 | 2021-2024 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $247.77 | 2022-2025 | Spiriva Respimat, Stiolto Respimat, Jascayd |
| Regeneron Healthcare Solutions, INC. | $236.05 | 2023-2025 | Dupixent |
| Pfizer INC. | $119.53 | 2019 | |
| Abbvie INC. | $115.96 | 2019 | |
| Verona Pharma, INC. | $111.98 | 2025 | Ohtuvayre |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $109.13 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $108.22 | 2021 | |
| Genzyme Corporation | $105.49 | 2023-2025 | |
| Grifols USA, LLC | $103.95 | 2024-2025 | Prolastin-C Liquid |
| Amgen INC. | $97.04 | 2022-2025 | Tezspire |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $95.44 | 2022 | |
| Sanofi-Aventis U.S. LLC | $94.99 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $84.28 | 2019 | |
| Philips North America LLC | $81.00 | 2025 | Vest Therapy Und |
| Takeda Pharmaceuticals U.S.A., INC. | $78.53 | 2022-2023 | Entyvio |
| Baxter Healthcare | $62.62 | 2024 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care |
| Viatris Specialty LLC | $49.49 | 2025 | Yupelri |
| Alexion Pharmaceuticals, INC. | $33.97 | 2024 | Ultomiris |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.02 | 2021 | |
| United Therapeutics Corporation | $23.02 | 2024 | Tyvaso |
| Novartis Pharmaceuticals Corporation | $21.95 | 2021 | |
| Viiv Healthcare Company | $21.43 | 2020 | |
| Chiesi USA, INC. | $21.18 | 2025 | Kengreal, Cleviprex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leandro Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.